Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Acquisitions & Divestments: 2015-2023

Historic Change in Acquisitions & Divestments for Seres Therapeutics (MCRB) over the last 9 years, with Dec 2023 value amounting to $23.0 million.

  • Seres Therapeutics' Change in Acquisitions & Divestments fell 64.97% to $11.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $85.8 million, marking a year-over-year decrease of 47.94%. This contributed to the annual value of $23.0 million for FY2023, which is 83.64% down from last year.
  • Seres Therapeutics' Change in Acquisitions & Divestments amounted to $23.0 million in FY2023, which was down 83.64% from $140.5 million recorded in FY2022.
  • Seres Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $169.6 million for FY2021, and its period low was $16.9 million during FY2019.
  • For the 3-year period, Seres Therapeutics' Change in Acquisitions & Divestments averaged around $111.0 million, with its median value being $140.5 million (2022).
  • In the last 5 years, Seres Therapeutics' Change in Acquisitions & Divestments slumped by 87.58% in 2019 and then skyrocketed by 254.85% in 2020.
  • Seres Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $16.9 million in 2019, then soared by 254.85% to $60.0 million in 2020, then soared by 182.78% to $169.6 million in 2021, then declined by 17.19% to $140.5 million in 2022, then tumbled by 83.64% to $23.0 million in 2023.